Which of the following is an adverse effect observed with evinacumab?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which of the following is an adverse effect observed with evinacumab?

Evinacumab, an ANGPTL3 monoclonal antibody given by IV infusion, commonly causes upper respiratory tract symptoms. Nasopharyngitis is a frequently reported adverse effect in its clinical trials and on the product label, reflecting inflammation of the nose and throat. While headaches, nausea, or rash can occur with many drugs, they are less consistently associated with evinacumab. Therefore, nasopharyngitis best matches the adverse effects observed with this medication.

Evinacumab, an ANGPTL3 monoclonal antibody given by IV infusion, commonly causes upper respiratory tract symptoms. Nasopharyngitis is a frequently reported adverse effect in its clinical trials and on the product label, reflecting inflammation of the nose and throat. While headaches, nausea, or rash can occur with many drugs, they are less consistently associated with evinacumab. Therefore, nasopharyngitis best matches the adverse effects observed with this medication.

More practice questions